
|Videos|April 19, 2022
Study Design and Outcomes of the Phase II REFINE Trial
Author(s)Naveen Pemmaraju, MD
A review of the study design and key efficacy and safety outcomes of the REFINE trial studying ruxolitinib plus navitoclax treatment in myelofibrosis.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5
































